Skip to content
Pages
Posts by category
News
- Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
- Recro Reports Inducement Grants for New Staff
- Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
- Recro to Present at H.C. Wainwright Global Life Science Conference
- Recro Reports Fourth Quarter and Year End 2020 Financial Results
- Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
- Recro Announces Amendment to Athyrium Credit Facility
- Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
- Recro Strengthens Leadership Team With Key Executive and Board Appointments
- Recro Grants Inducement Award to New Chief Executive Officer
- Recro Announces Executive Changes
- Recro Reports Third Quarter 2020 Financial Results
- Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
- Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
- Recro Reports Second Quarter 2020 Financial Results
- Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
- Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
- Regulatory and CMC Considerations for Developing Modified Release Versions of Immediate Release Oral Solid Dosage Forms, Upcoming Webinar Hosted by Xtalks
- Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
- Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
- Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
- COVID-19
- Recro Reports Financial Results for the Year Ended 2019
- Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
- Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
- Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
- Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
- Recro Pharma Reports Third Quarter 2019 Financial Results
- Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
- Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock
- FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application
- Recro Pharma Reports Second Quarter 2019 Financial Results
- Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
- Avoiding Potential Pitfalls: Phase Appropriate CMC Development and Regulatory Considerations, New Webinar Hosted by Xtalks
- Recro Pharma to Present at Upcoming Investor Conferences
- Recro Pharma Reports First Quarter 2019 Financial Results
- Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
- Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro
- Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
- Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
- Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
- Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
- Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
- Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
- Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
- Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
- Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
- Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
- Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro
- Recro Pharma Amends Athyrium Credit Facility
- Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
- Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology
- Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia
- Recro Pharma to Participate in Upcoming Investor Conferences
- Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018
- Recro Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck
- Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
- Recro Pharma Announces PDUFA Date for IV Meloxicam
- Recro Announces Expansion of CDMO Service Capabilities
- Recro Pharma to Participate in Upcoming Investor Conferences
- Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018
- Recro Pharma Provides Regulatory Update for IV Meloxicam
- Recro Pharma Reports Second Quarter 2018 Financial Results
- Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
- Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal
- Recro Pharma Receives Complete Response Letter from the FDA
- Recro Pharma Reports First Quarter 2018 Financial Results
- Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam
- Recro Pharma Announces Commercial Team Additions
- Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018
- Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
- Recro Hires Industry Veteran to Lead Business Development Team
- Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
- Recro Pharma Announces Commercial Team Additions
- Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
- Recro Pharma to Present at the 17th Annual Needham Healthcare Conference
- Recro Pharma to Present at Upcoming Investor Conferences
- Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
- Recro Pharma Announces Commercial Team Additions
- Recro Pharma Reports Year End 2017 Financial Results
- Recro Pharma to Host Analyst and Investor Day on February 28, 2018
- Recro Pharma to Host Analyst and Investor Day on February 28, 2018
- Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
- Recro Pharma Announces Key Sales Team Additions
- Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology
- Recro Pharma Announces Key Executive Promotions to the Financial Team
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Secures $100 Million Credit Facility
- Recro Pharma Reports Third Quarter 2017 Financial Results
- Recro Pharma to Present at Upcoming Investor Conferences
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting
- Recro Pharma to Participate in Upcoming Investor Conferences
- Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg
- Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
- Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Reports Second Quarter 2017 Financial Results
- Recro Pharma Submits New Drug Application for IV Meloxicam 30mg
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Acquires Novel Neuromuscular Blocking Agents
- Recro Pharma Added to the Russell 3000® Index
- Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference
- Recro Pharma Reports Inducement Grants for New Staff
- Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer
- Recro Pharma to Participate in Upcoming Investor Conferences
- Recro Expands Manufacturing Capabilities
- Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
- Recro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
- Recro Pharma Reports First Quarter 2017 Financial Results
- Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
- Recro Pharma to Present at the 16th Annual Needham Healthcare Conference
- Recro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference
- Recro Pharma Reports Year End 2016 Financial Results
- Recro Pharma Appoints Bryan Reasons to Its Board of Directors
- Recro Pharma to Present at Upcoming Investor Conferences
- Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam
- Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock
- Recro Pharma Announces Pricing of Public Offering of Common Stock
- Recro Pharma Announces Proposed Public Offering of Common Stock
- Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
- Recro Pharma Reports Third Quarter 2016 Financial Results
- Recro Pharma to Present at Upcoming Investor Conferences
- Recro Pharma Presents Clinical Data at PAINWeek 2016
- Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
- Recro Pharma Announces Closing of Public Offering of Common Stock
- Recro Pharma Announces Pricing of Public Offering of Common Stock
- Recro Pharma Announces Proposed Public Offering of Common Stock
- Recro Pharma Reports Second Quarter 2016 Financial Results
- Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
- Recro Pharma Appoints Michael Celano as Chief Financial Officer
- Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
- Recro Pharma Reports First Quarter 2016 Financial Results
- Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
- Recro Pharma Reports Year End 2015 Financial Results
- Recro Pharma to Present at the 28th Annual ROTH Conference
- Recro Pharma Appoints Fred Graff as Chief Commercial Officer
- Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
- Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
- Recro Pharma to Present at NobleCon12 Investor Conference
- Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
- Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
- Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
- Recro Pharma Reports Third Quarter 2015 Financial Results
- Recro Pharma to Participate in Upcoming Investor Conferences
- Recro Pharma Provides Pipeline Update
- Recro Pharma Appoints Karen A. Flynn to Its Board of Directors
- Recro Pharma Announces Presentations at PAINWeek 2015
- Recro Pharma Reports Second Quarter 2015 Financial Results
- Recro Pharma Announces Additional Information for Phase II Clinical Trial of Dex-IN
- Recro Pharma Appoints Scott Rizzo as General Manager
- Recro Pharma Announces Positive Top-Line Results for Phase II Clinical Trial of Dex-IN
- Recro Pharma Completes $16 Million Private Financing
- Recro Pharma Announces $16 Million Financing
- Recro Pharma to Present at the Jefferies 2015 Global Healthcare Conference
- Recro Pharma Reports First Quarter 2015 Financial Results
- Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes
- Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
- Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results
- Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing Facility and Business Unit From Alkermes
- Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
- Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference
- Recro Pharma Reports Third Quarter 2014 Financial Results
- Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
- Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
- Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
- Recro Pharma Reports Second Quarter 2014 Financial Results
- Recro Pharma Added to Russell Microcap(R) Index
- Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery
- Recro Pharma Reports First Quarter 2014 Financial Results
- Recro Pharma Announces New Board Members
- Recro Pharma Announces Closing of Initial Public Offering
- Recro Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
- Recro Pharma Announces Pricing of Its Initial Public Offering
Articles
Events
Team
- J. David Enloe, Jr.
- Ryan D. Lake
- Scott Rizzo, MBA, MMM
- Richard Sidwell, Ph.D.
- Bill Hirschman
- Shazib Jamil, MBA, MPH
- Carla Lusby, MBA
- David Smithwick, BS
- R. Wayne Wiley, RPh
- Sherida R. Vandiver, MBA, BS
- Cristin Grove
- Sandra Mathis
- Brittany L. Hayes, Ph.D.
- Maura Murphy, Ph.D.